Troubled Biotechs: Akesis, Metabasis, Xoma, Neurobiological Technologies
This article was originally published in The Pink Sheet Daily
Executive Summary
California nightmare? San Diego-based Akesis files for Chapter 7 bankruptcy while three other Golden State biotechs try to deal with their own financial maladies.
You may also be interested in...
Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
Usually, having more money that you know how to use is not considered a problem, but cash-rich Astellas may feel a bit stranded now that Gilead has trumped its bid to buy CV Therapeutics. But at least one analyst thinks the U.S. biotech sector still offers plenty of potential acquisitions for the Japanese pharma
Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
Japanese pharma drops lawsuit, ends its bid to buy cardiovascular-focused U.S. biotech, and hunts for other possibilities.
Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
Japanese pharma drops lawsuit, ends its bid to buy cardiovascular-focused U.S. biotech, and hunts for other possibilities.